BR112022015768A2 - Métodos de tratamento e prevenção de arritmias de enxerto - Google Patents

Métodos de tratamento e prevenção de arritmias de enxerto

Info

Publication number
BR112022015768A2
BR112022015768A2 BR112022015768A BR112022015768A BR112022015768A2 BR 112022015768 A2 BR112022015768 A2 BR 112022015768A2 BR 112022015768 A BR112022015768 A BR 112022015768A BR 112022015768 A BR112022015768 A BR 112022015768A BR 112022015768 A2 BR112022015768 A2 BR 112022015768A2
Authority
BR
Brazil
Prior art keywords
graft
prevention
treatment
methods
arrhythmias
Prior art date
Application number
BR112022015768A
Other languages
English (en)
Portuguese (pt)
Inventor
Knollmann Bjorn
Scott Thies Robert
Robb Maclellan William
Nakamura Kenta
E Murry Charles
Original Assignee
Univ Washington
Univ Vanderbilt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Washington, Univ Vanderbilt filed Critical Univ Washington
Publication of BR112022015768A2 publication Critical patent/BR112022015768A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0657—Cardiomyocytes; Heart cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/34—Muscles; Smooth muscle cells; Heart; Cardiac stem cells; Myoblasts; Myocytes; Cardiomyocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
    • A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/02—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from embryonic cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Vascular Medicine (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
BR112022015768A 2020-02-10 2021-02-09 Métodos de tratamento e prevenção de arritmias de enxerto BR112022015768A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062972330P 2020-02-10 2020-02-10
PCT/US2021/017220 WO2021163037A1 (en) 2020-02-10 2021-02-09 Methods of treating and preventing engraftment arrhythmias

Publications (1)

Publication Number Publication Date
BR112022015768A2 true BR112022015768A2 (pt) 2022-11-22

Family

ID=77291628

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022015768A BR112022015768A2 (pt) 2020-02-10 2021-02-09 Métodos de tratamento e prevenção de arritmias de enxerto

Country Status (11)

Country Link
US (1) US20230077983A1 (https=)
EP (1) EP4103206A4 (https=)
JP (1) JP2023512843A (https=)
KR (1) KR20220140532A (https=)
CN (1) CN115484966A (https=)
AU (1) AU2021218653A1 (https=)
BR (1) BR112022015768A2 (https=)
CA (1) CA3166678A1 (https=)
IL (1) IL295236A (https=)
MX (1) MX2022009807A (https=)
WO (1) WO2021163037A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3979997A1 (en) * 2019-06-06 2022-04-13 Novo Nordisk A/S Application of antiarrhythmic agents to stem cell derived cardiomyocytes and uses thereof
US20230250393A1 (en) * 2022-02-09 2023-08-10 University Of Washington Pre-treating cardiomyocytes with anti-arrhythmic drugs to reduce engraftment arrhythmia
WO2023173123A1 (en) * 2022-03-11 2023-09-14 Sana Biotechnology, Inc. Genetically modified cells and compositions and uses thereof
EP4593821A2 (en) * 2022-09-28 2025-08-06 Bluerock Therapeutics LP Compositions and methods for treating graft-related arrhythmia
WO2025137525A1 (en) * 2023-12-22 2025-06-26 Bluerock Therapeutics Lp Molecular identification of cardiomyocytes for cardiac cell therapy

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG192305A1 (en) * 2012-01-20 2013-08-30 Singapore Health Serv Pte Ltd Induced pluripotent stem cell (ipsc)-derived cardiomyocyte-like cells and uses thereof in screening for agents
US9994812B2 (en) * 2012-04-04 2018-06-12 University Of Washington Through Its Center For Commercialization Systems and method for engineering muscle tissue
US9855317B2 (en) * 2015-04-27 2018-01-02 Reflex Medical, Inc. Systems and methods for sympathetic cardiopulmonary neuromodulation
AU2018235964A1 (en) * 2017-03-15 2019-08-15 Cambridge Enterprise Limited Methods and compositions for enhancing cardiomyocyte maturation and engraftment
EP3979997A1 (en) * 2019-06-06 2022-04-13 Novo Nordisk A/S Application of antiarrhythmic agents to stem cell derived cardiomyocytes and uses thereof

Also Published As

Publication number Publication date
IL295236A (en) 2022-10-01
JP2023512843A (ja) 2023-03-29
MX2022009807A (es) 2022-11-10
AU2021218653A1 (en) 2022-09-01
EP4103206A4 (en) 2024-03-13
CN115484966A (zh) 2022-12-16
US20230077983A1 (en) 2023-03-16
KR20220140532A (ko) 2022-10-18
WO2021163037A1 (en) 2021-08-19
EP4103206A1 (en) 2022-12-21
CA3166678A1 (en) 2021-08-19

Similar Documents

Publication Publication Date Title
BR112022015768A2 (pt) Métodos de tratamento e prevenção de arritmias de enxerto
MX2022004051A (es) Composicion novedosa para el cuidado de la piel.
RU2017139096A (ru) Композиция, содержащая биосовместимый матрикс, способ получения композиции
MX2020007060A (es) Compuestos, composiciones y metodos para tratar enfermedades que involucren tejidos con enfermedades acidas o hipoxicas.
WO2020242896A3 (en) Treatment of angiopoietin like 7 (angptl7) related diseases
MX2017012125A (es) Metodo para promover crecimiento capilar e impedir perdida capilar de paciente, composicion para el mismo, y metodo para preparar composicion.
MX2024000828A (es) Formulaciones de parasiticida de isoxazolina y metodos para el tratamiento de la blefaritis.
WO2017043953A3 (es) Proceso de obtención de un compuesto de aspersión de células endoteliales microvasculares de piel y células madre mesenquimales y su método de aplicación para la regeneración tisular
ZA202211464B (en) Tetrahydroisoquinoline compounds as nrf2 activators
MX2022004056A (es) Composicion novedosa para el cuidado de la piel.
MX2022004052A (es) Composicion novedosa para el cuidado de la piel.
EP4585235A3 (en) Textured medical textiles
BR112021025701A2 (pt) Formulações e métodos de parasiticida de isoxazolina para tratar blefarite
AR128163A1 (es) Ácido láctico y análogos del mismo para uso en regular y/o promover el aumento de tejidos
MX368750B (es) Composiciones farmaceuticas semisolidas de base oleosa conteniendo pirfenidona para su aplicacion en la reparacion tisular.
ZA202211465B (en) Tetrahydroisoquinoline compounds as nrf2 activators
MX2024014755A (es) Composiciones de colágeno y métodos de uso de estas
MX2025005597A (es) Compuestos antisenescencia novedosos y composiciones de los mismos
MX2024015077A (es) Benzopirimidina-4(3h)-onas como inhibidores de pi3k
MX2021012353A (es) Composicion cosmetica topica y usos de la misma.
MX2022004055A (es) Composicion novedosa para el cuidado de la piel.
AR105752A1 (es) Métodos para el tratamiento de enfermedades cardiovasculares
BR112015022565A2 (pt) composições e métodos para aumentar o potencial terapêutico das células tronco
SA522431729B1 (ar) مركبات وطرق لعلاج أمراض متعلقة بالأوكسالات.
MX2022004048A (es) Composicion novedosa para el cuidado de la piel.

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]